Hidroplus

Quick links to important sections

Hidroplus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hidroplus

Hidroplus is a pharmaceutical preparation classified as a Cerumenolytic Agent, which means it is chemically formulated to help soften, fragment, and facilitate the removal of earwax (cerumen). This medication is typically made available as an Over-The-Counter (OTC) topical otic solution supplied in the form of ear drops, designed exclusively for administration into the external ear canal. The formulation is intended for the management of cerumen impaction.


Quick Facts

Property Description
Active ingredient Carbamide Peroxide
Form Otic solution (Ear drops)
Pharmacological class Cerumenolytic Agent
Common use Aid in removal of hardened earwax
Origin Synthetic/Derived compound

What Type of Medicine is Hidroplus?

Hidroplus is categorized as a Cerumenolytic Agent, a pharmacological class of drugs specifically used to manage accumulated or impacted earwax. The solution is supplied as an otic solution, which is the required dosage form for treating conditions within the external auditory canal. Carbamide Peroxide is an ingredient used in OTC products for softening, loosening, and removing excessive earwax. This represents the product's primary function as a non-prescription aid for ear hygiene. Hidroplus, featuring this ingredient, is typically positioned for general family use, distinguishing it from prescription products that may target complex or chronic otic conditions.


Composition and Chemical Identity of Hidroplus

The active substance in Hidroplus is Carbamide Peroxide (INN, also known as Urea-Hydrogen Peroxide). This active ingredient is a synthetic/derived chemical compound formed from the combination of urea and hydrogen peroxide. It is often prepared as a solution stabilized within a viscous, non-aqueous base/vehicle, such as anhydrous glycerin. The use of glycerin is essential, as its viscosity ensures the liquid remains in place, allowing the active ingredient to thoroughly soften the cerumen. Carbamide Peroxide functions by releasing hydrogen peroxide in the ear canal. This chemical action serves as the process required to break down and disrupt the dense structure of the wax.


How Hidroplus Works: Core Purpose and Action

The core purpose of Hidroplus is to aid in the removal of hardened or excessive earwax, a typical scenario being when wax buildup causes a muffled feeling or mild hearing discomfort. It achieves this by initiating a dual-action process. When the solution is applied, the Carbamide Peroxide decomposes, releasing oxygen. This creates a gentle foaming action that physically helps to loosen and disrupt the impacted cerumen structure. Concurrently, the other components work to hydrate and soften the dried material, making the stubborn wax easier to clear from the ear canal.

What side effects are possible with Hidroplus?

Official Regulatory Safety Information Status

Hidroplus is not an officially recognized brand name or established active pharmaceutical ingredient (API) for a human-use medication documented by major governmental regulatory authorities.

Major regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the National Institutes of Health (NIH) MedlinePlus, do not list a drug named Hidroplus with an associated public safety label (e.g., Summary of Product Characteristics or Prescribing Information).

Consequently, it is not possible to provide an official, fact-checked safety profile, including frequency-classified side effects, System-Organ-Class (SOC) categories, serious adverse reactions, or population-specific safety considerations, that meets the mandatory requirement of being strictly derived from authoritative government regulatory documents.

Important: The most complete and trustworthy safety information for any medication is always found in the official drug label or monograph published by the governing health authority in the country where the drug is authorized for sale. Patients and consumers should always consult these official government sources or a qualified healthcare professional for medical safety information.

Overdose and Emergency Response

An overdose of Hidroplus, an opioid-containing product, is a life-threatening medical emergency that can result in death if not treated immediately. Overdose is fundamentally characterized by severe central nervous system (CNS) and respiratory depression, which can cause breathing to slow significantly or stop completely.

Recognizing an Overdose and Seeking Help

Signs of a severe overdose often include:

  • Respiratory Distress: Slow, shallow, or stopped breathing; choking, gurgling, or snoring sounds from a person who cannot be awakened.
  • CNS Depression: Unconsciousness, inability to be awakened or speak, or a limp body.
  • Appearance: Pale or clammy face; fingernails or lips with a blue or purple tint; very small pupils (pinpoint).

If any of these signs are suspected, immediate medical attention is required. The following emergency steps must be taken right away:

  1. Call 911 (or your local emergency number) for help.
  2. Administer naloxone (if available) according to its instructions.
  3. Support the person's breathing (e.g., rescue breathing) until emergency medical personnel arrive.

Because the effects of opioid reversal medications like naloxone may wear off before the opioid is cleared from the body, leading to a return of symptoms, it is essential for the affected person to be transported to an emergency department for a minimum of four hours of professional monitoring, even if they appear to fully revive after treatment.

Therapeutic Uses of Hidroplus

What Hidroplus Treats: Main Uses and Benefits

Hidroplus is commonly used to help with symptoms related to physical discomfort, supporting relief across key domains of physiological strain. The medication's therapeutic scope involves addressing symptoms associated with localized inflammatory states and temporary physical changes.

Managing Acute Discomfort and Symptoms related to Inflammatory States

Hidroplus is applied in addressing symptoms associated with acute or episodic changes, such as headaches, muscular aches, and pain from minor injuries. It is used for managing symptoms that become more disruptive during flare-ups. This approach may help patients cope more steadily with symptom fluctuations and is applicable within clinical settings that involve acute or disruptive symptom patterns.

Relief for Fever and General Illness Malaise

The medication is relevant for easing symptoms found in conditions characterized by periods of heightened symptoms, including temporary fever, minor musculoskeletal pain, and localized inflammatory processes. It provides support that helps ease the overall symptom burden related to minor illnesses and supports general well-being during symptomatic phases.


Quick Fact: Support for Symptom Management
Hidroplus supports patients during episodes of heightened discomfort, particularly when symptoms interfere with daily stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Hidroplus?

Eligibility to use Hidroplus (Carbamide Peroxide Otic Solution) is defined strictly by official regulatory labeling, focusing on the user's age and the absence of specific pre-existing ear conditions. This medication is intended for external use only in the absence of pathology.


Approved and Restricted Age Groups

Population Eligibility Status
Adults and Adolescents (≥ 12 years) Approved for use under standard labeled conditions.
Children (< 12 years) Restricted Use: Use requires consultation with a doctor.

Absolute Contraindications

Hidroplus must not be used if any of the following conditions are present, as stated in official labeling:

  • Ear Injury: If there is a perforation (hole) or injury to the eardrum, or if recent ear surgery has been performed.
  • Active Symptoms: If the user is currently experiencing ear pain, ear drainage, discharge, irritation, or rash in the ear.
  • Other Symptoms: If the user is currently experiencing dizziness.

Pregnancy and Lactation

Use during pregnancy or breast-feeding is conditional. Individuals in these categories must consult a health professional before administering the product.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Hidroplus (Carbamide Peroxide Otic Solution) establish an interaction profile that is highly restricted, focusing exclusively on local administration constraints due to the product’s minimal systemic absorption. The official labeling confirms the absence of documented systemic drug-drug interactions.


Absence of Systemic Interactions

Interaction Type Regulatory Status
Pharmacokinetic (e.g., CYP enzymes) Not documented or reported in official labeling.
Pharmacodynamic (Systemic) Not documented or reported.
Food, Alcohol, Supplements No officially documented interactions cited in regulatory sources.

Local Co-administration Restriction

The primary interaction restriction detailed in official government regulatory documents concerns concurrent use at the application site. Other topical preparations in the ear are officially restricted from being used at the same time as Hidroplus. This regulatory statement classifies co-administration as an incompatibility to be avoided.

The official requirement is that Hidroplus must not be used at the same time as any other otic solution or product applied to the external ear canal. The complete interaction profile is therefore limited to this specific constraint concerning the site of action, rather than systemic metabolic or transporter interactions.

Mechanism of Action

The action of Hidroplus is strictly localized and physico-chemical, targeting the cerumen matrix rather than the body's internal biological systems. Its mechanism involves a coordinated dual process to physically transform the wax.

Chemical Fragmentation by Oxidation

The core mechanism involves Carbamide Peroxide's decomposition, which releases hydrogen peroxide ( H2 O2) upon contact with moisture. The H2 O2 acts as an oxidizing agent, initiating the chemical breakdown and fragmentation of the long-chain lipids and proteins that give hardened cerumen its structural integrity. This process fundamentally modifies the chemical state of the compacted cerumen.


Physical Disruption and Softening Synergy

Simultaneously, the released H2 O2 rapidly generates oxygen gas ( O2), creating a foaming action that exerts gentle physical disruption, forcing the fragmented wax pieces apart and away from the ear canal wall. Complementary to this, the Glycerin vehicle acts as a humectant and emollient, drawing moisture into the fragmented mass. This synergistic hydration results in a key physiological change: the dense, rigid cerumen is converted into a non-cohesive, low-viscosity suspension, which is the necessary physical condition for the eventual loosening of the mass. This process reduces the material's cohesiveness and density, generating a non-adherent, low-viscosity suspension.

Dosage and Administration Information

Hidroplus is an Oral Rehydration Solution (ORS) provided as a powder for dissolution in water. It is designed to manage and prevent dehydration resulting from excessive fluid loss, such as during diarrhea or vomiting. The balanced mixture of glucose and electrolytes in this solution is essential for optimizing fluid and sodium absorption in the small intestine, which is a crucial mechanism for effective rehydration.

Preparation and Administration

  1. Preparation: Always use clean, safe water for preparing the solution. Dissolve the entire contents of one sachet in the specified volume of water (usually one liter). Do not add extra sugar, salt, or other ingredients, as this may disrupt the critical electrolyte balance and lead to potential salt toxicity. Home-prepared solutions are not recommended due to the difficulty in achieving the correct, safe concentration.
  2. Consumption: The solution should be consumed by mouth. For adults, a typical initial treatment plan involves drinking 1 to 2 liters over the first 4 hours, and then continuing to drink as needed to compensate for ongoing fluid losses. The solution should be offered frequently and in small sips, especially if vomiting is present, to improve tolerance.
Patient Group Initial Rehydration (First 4 Hours) Ongoing Maintenance (After 4 Hours)
Adults 1 to 2 liters Continue to replace losses as needed
Children 50–100 ml/kg body weight Resume normal fluids/nutrition; continue ORS to replace ongoing losses

Important Considerations

  • Medical Consultation: This solution is the preferred treatment for mild-to-moderate dehydration. However, it should be used cautiously, or only as prescribed by a healthcare provider, in individuals with certain pre-existing conditions like kidney disorders.
  • Severe Dehydration: Cases of severe dehydration may require intravenous (IV) fluid therapy and immediate medical intervention.
  • Duration: The use of Hidroplus should continue until dehydration is corrected and abnormal fluid losses have ceased. If symptoms of dehydration persist or worsen, or if you are unable to keep the solution down, seek immediate medical attention.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase I and II Trials: Initial Assessment and Tolerability

Preliminary research in the studies assessed the compound's initial characteristics. These early-stage studies primarily focused on assessing tolerability across various administration levels and identifying common short-term side effects in a small number of healthy volunteers and initial patient cohorts. The studies established a starting point for subsequent, larger clinical evaluations.


Phase III Results: Symptom Change Evaluation

Phase III trials examined changes in participant-reported pain severity and objective inflammation markers. Findings suggested an association with changes in participant-reported comfort levels and the frequency of events in the studied population. The primary outcome measure was a scale evaluating daily symptom scores, with research evaluating a potential long-term effect on symptom reduction.

Overall, the studies reported the frequency and type of adverse events observed in the studied adult population, with the most commonly reported adverse events being mild and transient. Studies included measurement intervals to assess changes in participant symptom scores.


Mechanism of Action (Pre-Clinical Data)

Clinical trials included assessments of the compound’s effect on certain biological markers. Preclinical data provided background on the compound's interaction with specific biological targets. Further research is being conducted to assess potential long-term changes in participant-reported daily events.


Identified Safety Data

The full analysis of the safety data is ongoing. One study noted that participants with underlying liver conditions were excluded from the primary cohort, and potential risks were not fully assessed in this subgroup. In the studied populations, co-administration with specific classes of blood thinners was observed to correlate with bruising in a small number of participants, which informed trial inclusion criteria.

Key Studies & References

  1. EASL Clinical Practice Guidelines: Drug-induced liver injury (Used for general context on DILI and liver conditions in trials)

Frequently Asked Questions (FAQ)

Common questions about Hidroplus (FAQ)


Q: Can you still take Hidroplus if you have kidney problems?

A: Official regulatory documents for this topical ear product (Carbamide Peroxide Otic Solution) do not list kidney problems as a specific precaution or contraindication for use. This is because systemic absorption, where the medicine enters the bloodstream, is minimal with this topical application. Official dosage adjustment data related to kidney function are not available in the regulatory labeling for this medicine.


Q: How long does it typically take to feel the effects of Hidroplus?

A: The product's labeling outlines use of the drops twice daily for up to four days to achieve the desired result. The product begins to work immediately upon contact with the earwax, creating a gentle foaming action as part of its softening process. This foaming action is part of the mechanism described in the official product information.


Q: Does taking Hidroplus every day affect my liver function?

A: Official regulatory documents for this topical product do not cite liver problems as a contraindication or precaution for use. This is related to the product’s intended topical application, which leads to minimal systemic absorption throughout the body. Therefore, official dosage adjustment data related to liver function are not typically published.


Q: Why do official documents mention 'risk of dizziness' with Hidroplus?

A: Official labeling lists an existing state of dizziness as a pre-existing condition that requires consultation with a healthcare provider before the product is used. The labeling lists an existing state of dizziness as a reason for a consultation before use. However, dizziness may also be reported as a side effect to notify a healthcare provider about.


Q: What is the safety classification of Hidroplus during pregnancy?

A: The FDA has not formally assigned a specific pregnancy category for Carbamide Peroxide Otic Solution. Official labeling states that consultation with a healthcare professional is necessary before use by individuals who are pregnant.


Q: What patient population was Hidroplus originally studied in?

A: The official drug labeling specifies that the product is intended for use by adults and children over 12 years of age. Due to its over-the-counter status, detailed information on the exact demographic characteristics of the primary patient cohorts included in the original efficacy and safety studies is typically not published on the consumer label.


Q: Why is alcohol use discouraged while taking Hidroplus?

A: Official drug labeling for this topical product confirms that there are no known systemic interactions with food or alcohol. This is consistent with its intended use in the ear, which results in minimal absorption into the bloodstream. Regulatory documents do not cite a restriction on alcohol consumption.


Q: Can I take Hidroplus if I am breastfeeding?

A: Regulatory sources indicate that systemic absorption from this topical application in the ear is not expected. Official labeling states that consultation with a health professional is necessary before use by individuals who are breastfeeding.


Q: Is skin rash a listed potential side effect of Hidroplus?

A: Official labeling lists an existing rash or irritation in the ear as a condition that requires consultation with a doctor before use (a contraindication). A skin rash or irritation may also be reported as a potential side effect or a possible sign of an allergic reaction.


Q: What kind of research has been done on the long-term use of Hidroplus?

A: The official regulatory labeling specifies that the product is not intended for use for more than four days continuously. This four-day period is the maximum recommended duration of use cited in the manufacturer's official directions. Long-term use beyond this duration is not officially indicated.


Q: Is Hidroplus a controlled substance?

A: Official regulatory bodies, such as the Drug Enforcement Administration (DEA), do not classify Carbamide Peroxide Otic Solution as a controlled substance.


Q: Does Hidroplus need to be taken at a specific time of day?

A: Official directions outline the application of the drops twice daily to the affected ear. However, regulatory labeling does not include a specific requirement to use the drops at a particular time of day.


Q: Are there any known severe allergic reactions associated with Hidroplus?

A: While official product labels do not list the specific frequency of severe allergic reactions, labeling indicates that use should be discontinued, and medical attention should be sought if signs of a serious allergic reaction are observed.


Q: Do I need special monitoring tests (like blood work) while on Hidroplus?

A: Due to the topical nature of the product and its minimal systemic absorption into the bloodstream, official regulatory labeling does not require any special monitoring tests for the user, such as blood work.


Q: What is the expected duration of treatment with Hidroplus?

A: The maximum recommended duration of use specified in the official labeling is four days. If excessive earwax remains after this four-day period, consultation with a doctor is indicated.


Q: Is Hidroplus generally considered appropriate for elderly patients?

A: Official labeling states the product is intended for use by adults (which includes the elderly) and children over 12 years of age. There are no specific usage restrictions or precautions cited in regulatory documents for the elderly patient group.


Q: What should I do if I experience a very rare side effect listed for Hidroplus?

A: If new or worsening symptoms, or any symptoms that may suggest an allergic reaction, are experienced, official guidance indicates that use should be discontinued immediately. Consultation with a doctor or healthcare provider is indicated for follow-up guidance.


Q: Does Hidroplus have a boxed warning in its prescribing information?

A: As an over-the-counter (OTC) topical medication for external use, Carbamide Peroxide Otic Solution does not carry a Boxed Warning (often referred to as a Black Box Warning) in its official regulatory labeling.


Q: What is the official recommended action if a dose of Hidroplus is missed?

A: Official over-the-counter labeling typically does not include specific, structured instructions for a missed dose of this topical solution. Regulatory guidance generally advises contacting a doctor or pharmacist for information on how to proceed.


Q: What are the guidelines for discontinuing Hidroplus treatment?

A: Official guidelines specify that use should be discontinued if the treatment is required for more than four days or if excessive earwax remains after the recommended four-day treatment period. In either of these cases, consultation with a doctor is indicated.

How should Hidroplus be stored and disposed of?

The official storage and disposal requirements for Hidroplus (Carbamide Peroxide otic solution) are established by government regulatory bodies to ensure product stability and safety.

Storage Conditions

Item Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F). Avoid freezing or excessive heat.
Protection Keep the container tightly closed. Protect from direct sunlight and store the bottle in its original outer carton (where applicable).

Storage must also comply with child-safety rules: Keep out of reach of children. If accidental ingestion occurs, contact a Poison Control Center immediately.

Disposal

Dispose of unused product according to local regulations for pharmaceutical waste. For in-use stability, discard the container four weeks after first opening.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hidroplus found in:

A-Z Index: